Ascendis Pharma A/S（ASND）の株式分析ASNDAscendis Pharma A/S

Ascendis Pharma A/S is a Denmark‑based biopharmaceutical company operating within the life sciences and biotechnology sector. The Company scope of activity includes discovery, development, and commercialization of innovative therapies for rare diseases and serious chronic conditions with significant unmet medical needs where a clinically validated parent drug or pathway is suitable to company technologies. Ascendis Pharma A/S focuses on the endocrinology area and has a pipeline of three independent rare disease product candidates, such as Growth Hormone Deficiency (GHD), Hypoparathyroidism and Achondroplasia. The second therapeutic area is oncology, where the company focuses immunotherapy to targeted therapies. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Ascendis Pharma (ASND) appears to be a good buy right now due to its strong financial turnaround, evidenced by a net profit of €207 million in Q2 2026, a significant recovery from a net loss of €39 million a year ago. Additionally, the stock's current price of $243.37 is well below the average analyst price target of $287, suggesting potential upside. However, the main risk is the high RSI of 79.596, indicating the stock may be overbought in the short term.

6 analysts cover ASND: 5 rate it Buy, 1 Hold and 0 Sell. The average price target is 277.08.